E.Merck: Shifting focus - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

E.Merck: Shifting focus

Sep 18, 2001

E.Merck (India), subsidiary of the German multinational Merck, reported a healthy topline performance for 2QFY02. While the company managed to log double digit topline growth operating margins were under pressure. The growth in sales is primarily due to an upward price revision in its vitamin brand Neurobion in June 2000.

(Rs m)2QFY012QFY02%ChangeFY01
Sales 791 881 11.3% 3,134
Other Income 9 38 346.3% 67
Expenditure 628 716 14.0% 2,582
Operating Profit (EBDIT) 163 165 1.0% 552
Operating Profit Margin (%)20.6%18.7% 17.6%
Interest 1 1 50.7% 23
Depreciation 15 24 59.9% 72
Profit before Tax 156 178 14.0% 524
Other Adjustments    
Tax 44 53 20.1% 139
Profit after Tax/(Loss) 112 125 11.7% 385
Net profit margin (%)14.2%14.2% 12.3%
No. of Shares (eoy) (m) 17 17   17
Diluted Earnings per share* 26.6 29.7   22.9
P/E (at current price) 9 12
(*- annualised)    

E. Merck is a market leader in vitamins and derives over 60% of its turnover from this segment. Three of its vitamin brands Evion, Neurobion and Polybion contribute almost 40% of the company’s turnover. During the first half of the current year the company re-introduced Neurobin with better marketing focus. However, the pharma division showed a sluggish growth of 3% mainly on account of competition from generic players. The slow growth in pharma division was more than compensated by a 20% growth in non-pharma division comprising laboratory and speciality chemicals.

One of the major threats to the company is high price volatility in Vitamin E due to fierce competition from Chinese and European suppliers. To overcome this concern, the company is evaluating various options like better utilisation of plant capacity and outsourcing of ingredients. Over the last couple of years the company has made a mark in other therapeutic segments such as cardiology, topical anti–inflammatory and dermatologicals while maintaining its mark in the vitamins segment. Apart from launching new products, the company also acquired Livogen brand from Glaxo India Ltd.

At the current market price of Rs 263, the stock trades at 12x times its FY01 earnings. Valuations going forward would depend on the success in new therapeutic areas, which the company has ventured into.

Equitymaster requests your view! Post a comment on "E.Merck: Shifting focus". Click here!


More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 7, 2021 03:29 PM


  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks